Shots:
- Merck to receive ~$1.2B to supply ~1.7M courses of molnupiravir to the US government, if its receives EUA or approval from the US FDA and expects to have 10M+ courses of therapy available by the end of 2021
- The therapy is currently being evaluated in a P-III MOVe-OUT study in non-hospitalized patients with COVID-19. Merck also plans to file for EUA or approval outside the US
- Merck is collaborated with generic manufacturers to accelerate the availability of the therapy in 104 LMICs, following the approvals or EUA by local regulatory agencies & plans to initiate a clinical program of molnupiravir for post-exposure prophylaxis in H2’21
Click here to read full press release/ article | Ref: Business Wire | Image: Spagnola & Associates
The post Merck Signs ~$1.2B Supply Agreement with US Government for Molnupiravir to Treat COVID-19 first appeared on PharmaShots.
